NCT02796066

TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris

A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of TSN2898 Topical Gel for the Treatment of Acne Vulgaris

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Thesan Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 16 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the safety and effectiveness of TSN 2898 topical gel in the treatment of moderate to severe acne.

Detailed description

TSN2898 is an inhibitor of stearoyl-CoA desaturase-1 (SCD-1), an enzyme present in sebaceous glands and a key regulatory enzyme in lipogenesis. This study will assess the safety and efficacy of TSN2898 topical gel and matched gel vehicle, applied daily on the face for the treatment of moderate to severe acne vulgaris.

Conditions

• Acne Vulgaris

Interventions

Type	Name	Description
DRUG	Vehicle	Applied once a day
DRUG	TSN2898	Applied once a day
DRUG	TSN2898	Applied once a day
DRUG	TSN2898	Applied once a day

Timeline

• Start date: 2016-06-01
• Primary completion: 2017-02-01
• Completion: 2017-02-01
• First posted: 2016-06-10
• Last updated: 2017-04-26

Locations

6 sites across 3 countries: United States, Dominican Republic, Honduras